XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.
G
G

Galapagos


Berita

Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19

BRIEF-Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19 Aug 23 (Reuters) - Galapagos NV GLPG.AS : ECOR1 CAPITAL LLC REPORTS 9.9% STAKE IN GALAPAGOS NV AS OF AUG 19 - SEC FILING ECOR1 CAPITAL LLC SAYS BELIEVES GALAPAGOS NV'S SECURITIES ARE DEEPLY "UNDERVALUED" ECOR1 CAPITAL LLC - INTENDS TO COMMUNICATE WITH GALAPAGOS’ MANAGEMENT, BOARD
G

U.S. STOCKS Workday, Roku, Dexcom

BUZZ-U.S. STOCKS ON THE MOVE-Workday, Roku, Dexcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's stock indexes jumped on Friday, with the benchmark S&P 500 index nearing a record high, after U.S. Federal Reserve Chair Jerome Powell said "the time has come" to reduce interest rates.
G
I
Q
L
R
U
U

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open higher on Friday ahead of a speech from Federal Reserve Chair Jerome Powell that investors expect will offer hints on the pace of rate cuts in the world's biggest economy.
G
Q
R
U
E

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Friday with investors awaiting Federal Reserve Chair Jerome Powell's comments at the Jackson Hole Economic Symposium for clues on interest-rate cuts in the world's biggest economy.
G
R
U
E

Galapagos rises on FDA clearance for phase 1/2 1 study

BUZZ-Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study ** Shares in Galapagos GLPG.AS rise 2.7%, paring earlier gains of as much as 4%, after the Belgian biotech company obtained FDA clearance to initiate its ATALANTA-1 study with GLPG5101 in the U.S. ** "We see the FDA clearance as an important milestone for Galapagos' GLPG5101 program," says KBC Securities, adding the company will now be able to start treating patients in the U.S.
G
K

Galapagos: FDA Clears IND Application For Phase 1/2 1 Study

BRIEF-Galapagos: FDA Clears IND Application For Phase 1/2 ATALANTA-1 Study Aug 23 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 ATALANTA-1 STUDY OF CD19 CAR-T, GLPG5101, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA Source text for Eikon: ID:nGNX1gGlDF Further company coverage: GLPG.AS (Gdansk N
G

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up
A
A
A
A
B
B
B
C
C
D
D
E
G
G
H
H
H
I
K
O
B

U.S. STOCKS Morgan Stanley, Intel, Guardant

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intel, Guardant Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq Composite was set to plunge into a correction on Friday, falling more than 10% from its July peak after weak employment numbers aggravated worries of a slowdown in the U.S.
A
B
C
C
G
I
J
M
M
N
Q
A
U
A
M
U
U
C
C

U.S. STOCKS Intel, Nvidia, Chevron

BUZZ-U.S. STOCKS ON THE MOVE-Intel, Nvidia, Chevron Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were poised to slump at the open on Friday after weak employment numbers exacerbated worries of a slowdown in the U.S.
A
B
C
G
I
M
M
N
Q
A
U
A
U
C

U.S. STOCKS MercadoLibre, DoorDash, Coinbase

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, DoorDash, Coinbase Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures fell sharply on Friday after Amazon and Intel presented downbeat forecasts as concerns over the health of the U.S.
A
B
C
G
I
M
M
N
Q
A
A
U
B

Galapagos slips after it pauses drug candidate study

BUZZ-Galapagos slips after it pauses drug candidate study ** Shares in Galapagos GLPG.AS slide around 4% as the Belgian biotech company said it was temporarily pausing a drug candidate trial after one observed case of Parkinsonism ** The company said it would pause enrolment in the Phase 1/2 PAPILIO-1 for its drug candidate GLPG5301 in relapsed/ref
G

Galapagos NV reports results for the quarter ended in June - Earnings Summary

Galapagos NV reports results for the quarter ended in June - Earnings Summary Galapagos NV GLPG.AS reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 8 cents. The lone analyst forecast for the quarter was for a loss of 21 cents per share.
G

Galapagos Says FY Outlook Reaffirmed, Total Net Revenues For HY 140.3 Mln Euros

BRIEF-Galapagos Says FY Outlook Reaffirmed, Total Net Revenues For HY 140.3 Mln Euros Aug 1 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS NV: 2024 OUTLOOK REAFFIRMED: GALAPAGOS NV: TOTAL NET REVENUES FOR SIX MONTHS ENDED 30 JUNE 2024 AMOUNTED TO EUR 140.3 MILLION GALAPAGOS NV - HY OPERATING LOSS 71.3 MILLION EUROS VERSUS 27.7 MILLION EUROS Source te
G

Galapagos NV <GLPG.OQ> expected to post a loss of 4 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 4 cents a share - Earnings Preview Galapagos NV GLPG.OQ , GLPG.O is expected to show a fall in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Malines (mechelen) Antwerpen-based company is expected to report a 56.8% decrease in revenue to €64.75 million from €149.95 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
G

Galapagos tops BEL20 on encouraging trial data for cancer treatment

BUZZ-Galapagos tops BEL20 on encouraging trial data for cancer treatment ** Shares in Galapagos GLPG.AS rise 4 % after the Belgian biotech company presented "encouraging" new data for its blood cancer treatment GLPG5101 on Friday ** Galapagos says "no unexpected safety findings were observed and treatment with GLPG5101 resulted in high complete res
G

Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024

BRIEF-Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024 Galapagos NV GLPG.AS : GALAPAGOS PRESENTS ENCOURAGING NEW DATA FOR CD19 CAR-T CANDIDATE GLPG5101 IN NON-HODGKIN LYMPHOMA AT EHA 2024 GALAPAGOS NV - GLPG5101 SHOWED AN ENCOURAGING SAFETY PROFILE WITH MOST TEAES OF GRADE 1 OR 2 IN ONGOI
G



Syarat

Aset Popular

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.